Differences of actionable genomic alterations between patients with and without hypertension in non-small cell lung cancer

In this study, we carried out targeted next-generation sequencing (NGS) of tumor tissue samples from 64 NSCLC patients by a hybridization capture-based panel. The differences in somatic mutations, somatic interactions, key signaling pathways, functional biological information, and clinical actionability for the therapy of targeted agents were explored between NSCLC patients with hypertension (n=16) and without hypertension (n=48).